1. Home
  2. LABT vs YDKG Comparison

LABT vs YDKG Comparison

Compare LABT & YDKG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lakewood-Amedex Biotherapeutics Inc. Common Stock

LABT

Lakewood-Amedex Biotherapeutics Inc. Common Stock

N/A

Current Price

$2.29

Market Cap

5.3M

Sector

Health Care

ML Signal

N/A

YDKG

Yueda Digital Holding Class A Ordinary Share

HOLD

Current Price

$1.09

Market Cap

5.3M

ML Signal

HOLD

Company Overview

Basic Information
Metric
LABT
YDKG
Founded
N/A
2005
Country
United States
China
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Advertising
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
5.3M
5.3M
IPO Year
2026
2007

Fundamental Metrics

Financial Performance
Metric
LABT
YDKG
Price
$2.29
$1.09
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
191.1K
20.1K
Earning Date
N/A
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.66
$0.02
52 Week High
$6.85
$3.90

Technical Indicators

Market Signals
Indicator
LABT
YDKG
Relative Strength Index (RSI) 43.95 58.16
Support Level $2.07 $0.81
Resistance Level $2.48 $1.15
Average True Range (ATR) 0.21 0.06
MACD 0.03 -0.00
Stochastic Oscillator 39.64 57.14

Price Performance

Historical Comparison
LABT
YDKG

About LABT Lakewood-Amedex Biotherapeutics Inc. Common Stock

Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.

About YDKG Yueda Digital Holding Class A Ordinary Share

Yueda Digital Holding is a Web3 and digital company with a focus on the long-term accumulation of mainstream cryptocurrencies. The business activities of the company include active treasury management of mainstream digital assets, exploration of compliant, risk-managed yield opportunities, such as staking, on-chain liquidity provision, and other conservative market activities, selective investments and partnerships in Web3 infrastructure and applications, and advisory services for enterprises entering the digital-asset economy.

Share on Social Networks: